Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) General Counsel Jeff Cislini sold 6,000 shares of the company's stock in a transaction on Friday, October 11th. The stock was sold at an average price of $50.17, for a total transaction of $301,020.00. Following the transaction, the general counsel now owns 45,634 shares of the company's stock, valued at $2,289,457.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Revolution Medicines Trading Down 0.5 %
Shares of RVMD opened at $48.99 on Wednesday. The stock has a market capitalization of $8.18 billion, a P/E ratio of -13.46 and a beta of 1.43. The firm's fifty day simple moving average is $44.35 and its two-hundred day simple moving average is $41.03. Revolution Medicines, Inc. has a 12 month low of $15.44 and a 12 month high of $51.00.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.04). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.81 million. Revolution Medicines's quarterly revenue was down 73.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.92) earnings per share. As a group, research analysts predict that Revolution Medicines, Inc. will post -3.35 EPS for the current fiscal year.
Hedge Funds Weigh In On Revolution Medicines
Next opportunity for crypto millions
From Crypto 101 Media | Ad
According to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin is poised to reach six-figures, no matter who wins the U.S. presidential election…"
And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Coins that you may not have even heard of before could shoot up 10x, 20x, maybe even 150x in the coming months…
Just click here to request my "Bull Run Millionaire Blueprint" now.
Institutional investors and hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its position in shares of Revolution Medicines by 55.8% during the 3rd quarter. GAMMA Investing LLC now owns 620 shares of the company's stock worth $28,000 after purchasing an additional 222 shares in the last quarter. Headlands Technologies LLC raised its holdings in shares of Revolution Medicines by 140.9% in the 1st quarter. Headlands Technologies LLC now owns 1,513 shares of the company's stock worth $49,000 after acquiring an additional 885 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of Revolution Medicines in the 1st quarter worth about $104,000. EntryPoint Capital LLC acquired a new stake in shares of Revolution Medicines in the 1st quarter worth about $107,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Revolution Medicines by 10.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company's stock worth $131,000 after acquiring an additional 320 shares during the last quarter. Institutional investors own 94.34% of the company's stock.
Analyst Ratings Changes
Several brokerages have recently issued reports on RVMD. Barclays upped their price target on shares of Revolution Medicines from $54.00 to $60.00 and gave the stock an "overweight" rating in a report on Friday, September 27th. Jefferies Financial Group started coverage on shares of Revolution Medicines in a research note on Monday, July 8th. They issued a "buy" rating and a $63.00 price objective on the stock. Oppenheimer boosted their price objective on shares of Revolution Medicines from $45.00 to $55.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 16th. Wedbush reissued an "outperform" rating and issued a $59.00 price objective on shares of Revolution Medicines in a research note on Thursday, August 8th. Finally, Bank of America boosted their price objective on shares of Revolution Medicines from $48.00 to $55.00 and gave the stock a "buy" rating in a research note on Tuesday, July 16th. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $54.00.
Read Our Latest Stock Report on Revolution Medicines
About Revolution Medicines
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
